Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario

Immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy (CT) are effective therapeutic agents for the palliative treatment of metastatic non-small-cell lung cancer (NSCLC); the aim of our study was to investigate the acute and chronic renal toxicities in this setting. We collected data o...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-04, Vol.10 (5), p.679
Main Authors: Trevisani, Francesco, Di Marco, Federico, Floris, Matteo, Pani, Antonello, Minnei, Roberto, Scartozzi, Mario, Cirillo, Alessio, Gelibter, Alain, Botticelli, Andrea, Rijavec, Erika, Cattaneo, Monica, Garrone, Ornella, Ghidini, Michele
Format: Article
Language:English
Subjects:
Body mass index
Carboplatin
Chemical compounds
Chemotherapy
Cisplatin
Creatinine
Decay
Diabetes
Disease
Drug dosages
Epidermal growth factor receptors
Hypertension
Immune checkpoint inhibitors
immunotherapy
Inhibitors
Lung cancer
Lung carcinoma
Metastases
Metastasis
Non-small cell lung carcinoma
onconephrology
Patients
Pharmacology
Platinum
Renal function
renal toxicity
Small cell lung carcinoma
Toxicity
Tumor necrosis factor-TNF
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy (CT) are effective therapeutic agents for the palliative treatment of metastatic non-small-cell lung cancer (NSCLC); the aim of our study was to investigate the acute and chronic renal toxicities in this setting. We collected data on 292 patients who received cisplatin (35%), carboplatin-based regimens (25%), or ICI monotherapy (40%). The primary and secondary outcomes were compared to the acute kidney injury (AKI) rate and the mean estimated GFR (eGFR) decay between groups, respectively, over a mean follow-up duration of 15 weeks. We observed 26 AKI events (8.9%), mostly stage I AKI (80.7%); 15% were stage II AKI, 3.8% were stage III, and none required renal replacement therapy or ICU admission. The AKI rates were 10.9%, 6.8%, and 8.9% for the cisplatin, carboplatin, and ICI groups, respectively, and no significant differences were observed between the groups ( = 0.3). A global mean eGFR decay of 2.2 mL/min was observed, while for the cisplatin, carboplatin, and ICI groups, the eGFR decay values were 2.3 mL/min, 1.1 mL/min, and 3.5 mL/min, respectively. No significant differences were observed between the groups. Cisplatin/carboplatin-based CT and ICIs resulted in a similar incidence of AKI and eGFR decay, suggesting the safety of their cautious use, even in CKD patients.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10050679